Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483861 | 0.91 | MAPT (0.40) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL483882 | 0.89 | NPC1 (0.40) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL483637 | 0.87 | NPC1 (0.45) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16197860 | 0.87 | NPC1 (0.45) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16197859 | 0.87 | NPC1 (0.45) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL483962 | 0.87 | NPC1 (0.43) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL483960 | 0.87 | NPC1 (0.43) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15618609 | 0.85 | NPC1 (0.50) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15618613 | 0.85 | NPC1 (0.50) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15618611 | 0.85 | NPC1 (0.50) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2072505-B1 | A process for the preparation of oxazolidinone derivatives | DIPHARMA FRANCIS SRL (IT) | 2012-02-01 | — | — | EP | claimed |
| EP-2072505-A2 | A process for the preparation of oxazolidinone derivatives | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | claimed |
| US-20090156806-A1 | Process for the Preparation of Oxazolidinone Derivatives | DIPHARMA FRANCIS S.R.I. (IT) | 2009-06-18 | — | — | US | claimed |
| EP-2072505-B1 | A process for the preparation of oxazolidinone derivatives | DIPHARMA FRANCIS SRL (IT) | 2012-02-01 | — | — | EP | disclosed |
| EP-2072505-A2 | A process for the preparation of oxazolidinone derivatives | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | disclosed |
| US-20090156806-A1 | Process for the Preparation of Oxazolidinone Derivatives | DIPHARMA FRANCIS S.R.I. (IT) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156806-A1 | Process for the Preparation of Oxazolidinone Derivatives | OXA1L, AAAS, MLYCD | MAPT 2874/4885NPC1 4601/4885ALDH1A1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.